Stockwatch

RepliCel Life Sciences Inc (2)
Symbol	RP
Shares Issued	65,001,560
Close 2023-08-08	C$ 0.155
Market Cap	C$ 10,075,242
Recent Sedar+ Documents

RepliCel Life Sciences appoints Mackay as director

2023-08-09 14:03 ET - News Release

Subject: RepliCel Life Sciences Inc. Word Document File: '\\swfile\EmailIn\20230809 103423 Attachment Jamie Mackay Board of Directors Press Release.DOCX' 2 | Page NEWS RELEASE 1 | Page RepliCel Adds an Additional Director RepliCel Life Sciences Strengthens Its Board of Directors as focus shifts towards Commercialization VANCOUVER, BC, CANADA - August 9, 2023 - RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics,, is pleased to announce it has appointed Jamie Mackay to the Company's Board of Directors. Jamie Mackay is currently the CEO of Mackay Developments, Founder of Wheelhaus, Fireside Resorts and Vurtical. Jamie has extensive experience in large commercial, residential, and mixed-use real estate developments across the United States. Jamie, as a seasoned entrepreneur, has successfully managed numerous private startups. Having engaged with numerous entities across many different sectors as both an investor and as a member of management, Jamie brings a unique perspective. "Jamie has been integral in assisting management in laying groundwork as RepliCel prepares to commercialize multiple products. It has been a pleasure working with Jamie and I am excited to have him join the Board of Directors," Andrew Schutte President and CEO stated. "Jamie's expertise is vital as RepliCel transitions to a commercial entity." About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles. The Company's cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical study evaluating efficacy for the treatment of male and female hair loss due to androgenetic alopecia. This ongoing study is being funded by Shiseido Company Limited pursuant to a license agreement which has now been terminated but is the subject of an arbitration regarding Shiseido's rights to the product for Asia. RepliCel maintains the undisputed rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel maintains the rights to these products outside of Greater China. RepliCel has also developed a proprietary injection device (DermaPreciseTM) and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the DermaPrecise(TM) device and consumables in Greater China for dermatology applications and is expected to first launch the product in Hong Kong upon it being approved for market launch in either the United States or Europe. MainPointe Pharmaceuticals has an exclusive distribution agreement for the DermaPrecise(TM) device and consumables in the United States, subject to income. MainPointe is expected to fund the FDA approval process in the United States. Please visit replicel.com for additional information. Notable Facts: RepliCel's three cell therapy products have now been tested in over 100 patients in four countries on three continents. RepliCel now has key strategic regional partners each of which are now investing heavily in the further clinical testing and development of RepliCel's products for their markets. Data from each of the clinical programs will strengthen the product development initiatives for RepliCel and its other partners worldwide. For more information, please contact: Andrew Schutte, CEO and President 604-248-8693 info@replicel.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.